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ABSTRACT:
Although the mortality rate of endometrial cancer is comparatively low in 
gynecologic malignancies, a rising trend of this cancer has been observed for the 
past decade. The understanding of the molecular mechanism will favor for the clinical 
management of this disease. Aberrant activation of Wnt/β-catenin signaling pathway 
plays a major role in the pathogenesis of endometrioid adenocarcinoma including 
this cancer type. In this study, we reported that Sox7, one of Sox transcriptional 
factors, was frequently underexpressed in endometrial cancer and importantly, 
it was associated with dysregulation of the Wnt/β-catenin signaling activity. 
Immunohistochemical and quantitative RT-PCR analyses showed that Sox7 was 
underexpressed and was associated with high-grade tumor (P=0.021), increased 
expressions of β-catenin (P=0.038) and its downstream targets; CyclinD1 (P<0.001) 
and FGF9 (P<0.001). In addition, using HEK293T cell model, we found that Sox7 
was able to inhibit TCF/LEF-1-dependent luciferase activity induced by Wnt-1. This 
was further proved by that Sox7 could significantly suppress the expressions of Wnt 
targets; Cyclin D1 and C-myc in endometrial cells. Immuno-fluorescent microscopy 
revealed that Sox7 was co-localizaed with either mutant β-catenin or TCF4 protein 
in nucleus, while co-immunopreciptation assay demonstrated that Sox7 could 
physically interact with not only wild-type but also mutant β-catenin, as well as 
TCF4 proteins. Functionally, enforced expression of Sox7 could significantly inhibit 
endometrial or endometrioid ovarian cancer cells (OEA) harboring either wild-type or 
mutant β-catenin. These data suggest Sox7 is a negative regulator of Wnt/β-catenin 
signaling pathway through impeding the transcriptional machinery of β-catenin/TCF/
LEF-1 transcriptional complex, and the loss of expression may be involved in the 
pathogenesis of endometrial cancer. 
INTRODUCTION
Endometrial carcinoma is one of the common 
female malignancies in the western countries but it is 
getting common in Asian including Hong Kong Chinese. 
According to the Hong Kong Cancer Registry from 
1999 to 2007, endometrial carcinoma has increased 
from the ninth to the fourth most common gynecologic 
malignancies for females overall in Hong Kong (Hong 
Kong Cancer Registry 2007). Although the mortality 
rate of this disease is keeping at approximately 1.0%, 
a significant increase for the incidence trend has been 
revealed from 1999 to 2007 (Hong Kong Cancer Registry 
2007). This indicates endometrial cancer becomes more 
common in Hong Kong women nowadays. There are 
two primary types of endometrial cancer according to 
histopathology, cell biology and clinical course [1]. 
Endometrioid adenomacarcinoma or Type I carcinoma 
are the most common type and estrogen-related, often 
preceded by hyperplasia. Type II or non-endometrioid 
endometrial cancer usually exhibit serous or clear cell 
differentiation and estrogen-independent. 
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Wnt/β-catenin or canonical Wnt signal transduction 
pathway is a conserved molecular mechanism in 
metazoan animals. This signaling pathway regulates 
a remarkable variety of cellular process such as cell 
fate, cell proliferation, cell survival, cell behavior and 
migration [2]. In this pathway, β-catenin is the most 
effector for the regulation of Wnt/β-catenin targets. 
The stability of β-catenin is regulated by a multiprotein 
complex such as glycogen synthase kinase-3β (GSK3β) 
and casein kinase 1 (CK1), and the scaffolding proteins 
adenomatous polyposis coli (APC), Axin1 and Axin2 
(conductin). Aberrant activation of this pathway due to the 
accumulation of β-catenin is commonly found in human 
cancers [3-6]. Mounting evidences have revealed that the 
oncogenic mutations in β-catenin, APC and Axins are 
often associated with the upregulation of β-catenin and the 
pathogenesis of endometrioid-type of endometrial cancer 
and ovarian cancer [7-10]. The accumulated β-catenin 
eventually translocates into nucleus promotes tumor 
progression through its persistent interaction with one or 
more of its numerous downstream targets such as TCF/
LEF factor. Therefore, promoting β-catenin degradation 
by targeting the upstream sites of Wnt/β-catenin pathway 
is a rational approach for the therapy of cancers [11, 12]. 
However, most of human cancers including endometrial 
cancer (38%) harbor mutations on serine/threonine 
residues (codons 33, 37, 41, and 45) of β-catenin [13-15]. 
This causes difficulties of using above ways to inhibit the 
aberrant activation of Wnt/β-catenin signaling pathway in 
this disease.
In this study, we identified Sox7, one of the Sox 
transcription factors family, was significantly down-
regulated in high-grade endometrial cancer and inversely 
correlated with Wnt/β-catenin signaling activity. Enforced 
expression of Sox7 could remarkably suppress not only 
Wnt/β-catenin signaling and its downstream oncogenes, 
but also endometrial cancer cell growth. Importantly, 
we demonstrated that Sox7 inhibited Wnt/β-catenin 
signaling in endometrial or endometrioid ovarian cancer 
cells (OEA) harboring not only wild-type but also mutant 
β-catenin. Our findings manifest the significance of Sox7 
in the pathogenesis and the regulatory mechanisms of 
aberrant activation of Wnt/β-catenin signaling activity in 
endometrial cancer. This new knowledge generated may 
reveal novel strategies for rational design of Wnt/β-catenin 
inhibiting agents to combat this cancer.
MATERIALS AND METHODS
Clinical samples and cell lines
Surgical resection of 43 tumor samples from primary 
endometrial cancer patients and 37 normal endometrial 
samples from benign diseases such as uterine fibroid after 
surgery were randomly chosen for Q-PCR analysis. The 
histology of all endometrial cancer tissue samples have 
been verified by surgical pathologists. The histological 
subtype and stage of the tumors were categorized 
according to International Federation of Gynaecology 
and Obstetrics (FIGO) classification. Written informed 
consent was taken and the use of these clinical samples 
was approved by Institutional Review Board of the 
University of Hong Kong/ Hospital Authority Hong Kong 
West Cluster (HKU/HA HKW IRB)(Institutional Review 
Board number: UW08-069). Five endometrial cancer cell 
lines (RL95, KLE, HEC-1A and HEC-1B) (America Type 
Culture Collection, Rockville, MD, USA) and Ishikawa 
(ECACC 99040201, Sigma, St. Louis, MO) were used 
for investigation of Sox7 functions. Human Embryonic 
Kidney 293 cells (HEK 293) (ATCC) was used for TOP/
FOP luciferase reporter assay, and L Wnt3A cell line 
(CRL-2647) was used for Wnt3A conditioned medium 
(ATCC). The cell lines authentication was done by in-
house STR DNA profiling analysis and were cultured at 
37ºC in 5% CO2 in Dulbecco’s modified Eagle medium 
(DMEM/F12) (Gibco-BRL, Gaithersburg) with 10% fetal 
bovine serum (Gibco) and 1% Penicillin-Streptomycin 
(Gibco). 
Plasmids and cell transfection
The Flag/Sox7 expressing plasmid (gift from Dr. 
Hayashi Y, Department of Genetics, Nagoya University, 
Japan) was for ectopic expression of Flag-tagged Sox7 
fusion protein. The Sox7 cDNA was subcloned into 
pEGFP-C1 (Clontech, Mountain View, CA, USA) to 
generate GFP/Sox7 expressing plasmid. The HA/β-
catenin expressing plasmid (gift from Dr. Muller AG, 
Max-Planck-Institut, Germany) and the GFP/mutant 
β-catenin S37A expressing plasmid (gift from Dr. Wong 
AS, School of Biological Sciences, The University of 
Hong Kong, Hong Kong) were used for expressing wild-
type and mutant β-catenin respectively. The Myc/TCF4 
expressing plasmid (gift from Dr. Idogawa M, cancer 
Research Institute, Sapporo Medical University, Japan) 
was used for expressing Myc/TCF4 fusion protein. The 
pSuper8XTOPFlash and pSuper8XFOPFlash plasmids 
(gift from Dr. Moon R, University of Washington, 
USA) were used for TOP/FOP luciferase reporter assay. 
The pLNCX-Wnt1 construct (kindly provided by Dr. 
M. Semenov, Harvard University, USA) was used for 
induction of Wnt/β-catenin activity. LipofectamineTM 
LTX was used for cell transfection according to the 
manufacturer’s instructions (Invitrogen Life Technologies, 
Carlsbad, CA, USA).
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RNA extraction and real time quantitative RT-
PCR
The total RNA was isolated from clinical samples 
and cell lines by TRIzol reagent (Invitrogen). The cDNA 
was synthesized using Reverse transcription reagent kit 
(Applied Biosystems, Foster City, CA, USA). Real time 
quantitative reverse transcriptase-PCR (Q-PCR) was 
used for evaluating the expressions of Sox7, FGF9, SFN, 
Cyclin D1 and C-myc using Taqman® Gene expression 
Assays; human Sox7 (Assay ID: Hs00846731_s1), 
human FGF9 (Assay ID: Hs00181829_m1), human SFN 
(Assay ID: Hs00968567_s1), human Cyclin-D1 (Assay 
ID: Hs00765553_m1) and human C-myc (Assay ID: 
Hs00153408_m1), in an ABI PRISM™ 7500 system 
(Applied Biosystems). The human 18S rRNA (Assay ID: 
Hs99999901_m1) was used as an internal control.
Western blot and co-immunoprecipitation assays 
Cell lysate was prepared from cells using 
lysis buffer (Cell Signaling Technology, Darvers, 
MA, USA) containing protease inhibitor (Sigma) 
and Phenylmethylsulfonyl fluoride (PMSF) (Sigma 
Chemical Co., St Louis, MO, USA). The equal amount 
of protein samples was separated by 10% SDS-PAGE and 
electroblotted onto the Hybond-P membranes (Amersham 
Pharmacia Biotech, Cleveland, OH, USA). Blots were 
blocked with 5% skim milk, followed by incubation with 
β-catenin (Cell Signaling) and C-Myc (N262) (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), Cyclin-D1 
(Cell Signaling), anti-HA (Roche Applied Science, 
Indianapolis, IN, USA), anti-GFP (Santa Cruz), anti-
Flag and β-actin (Sigma) overnight at 4oC. Blots were 
then incubated with anti-mouse or anti-rabbit (Amersham 
Pharmacia Biotechnology) secondary antibodies 
conjugate with horseradish peroxidase for 1 hour in room 
temperature and visualized using ECLTM Western Blotting 
Detection Reagent (Amersham). 
For co-immunoprecipitation assay, HEK293 cells 
were transiently co-transfected with Flag/Sox7 and HA/β-
catenin, or GFP/mutant β-catenin, or Myc/TCF4 plasmids. 
The procedure of immunoprecipitation was performed as 
previously described [16, 17]. 
Immunohitochemical and Immunofluorescent 
analyses
For immunohistochemical analysis, a commercial 
ovarian cancer tissue array (EMC1501, Pantomics Inc, San 
Francisco, CA) was immunostained with primary rabbit 
polyclonal anti-Sox7 (R&D Systems, Minneapolis, MN 
USA) in 1:250 dilution, anti-β-catenin (BD Biosciences, 
St Jose, CA, USA) in 1:400 dilution, and anti-FGF9 
(Santa Cruz) in 1:200 dilution. The immunoreactivity of 
immuno-positive sample was determined by multiplying 
the intensity of the staining (+1, faint, +2 moderate, +3 
strong and +4 very strong) and percentage of stained area 
(0-100%). The mean of immunoreactivity value of normal 
and borderline cases was used to normalize all cases. The 
examination and scoring of all tissues were done by two 
investigators independently.
For immunofluorescent analysis, HEC1B cells 
were cultured on cover slips and transiently transfected 
with either RFP/Sox7 or GFP/mutant β-catenin S37A, 
or GFP/Sox7 and Flag/TCF4 and Myc/TCF4 expressing 
plasmids. After 24 hours, the transfected cells were fixed 
with 4% paraformaldehyde, treated with 0.1% Triton, 
incubated with anti-Flag (Sigma) and Alexa Fluor® 
Fluorescent Streptavidin Conjugates (Invitrogen), 
followed by counter-stained with DAPI (4’,6-diamidino-
2-phenylindole) (Invitrogen), the fluorescent signals were 
examined and photographed by fluorescent microscopy 
(Leica Q550CW).
Luciferase Reporter Assay
HEK293 cells were seeded in 24-well plates and 
transiently transfected with various amounts (0, 250 
and 500 ng) of Flag/Sox7, 100 ng pLNCX-Wnt1, a 
pSuper8XTOPFlash or pSuper8XFOPFlash luciferase 
reporter constructs. All transfections were normalized with 
pcDNA vector and incubated for 24 hours. The luciferase 
activity was measured using the Dual-luciferase Reporter 
Assay System (Promega) and transfection efficiency 
was normalized with Renilla luciferase activity. All 
experiments were repeated in 3 independent experiments.
Cell viability analysis
Cell viability was evaluated by Cell Proliferation 
Kit II (XTT) for 5 days according to the manufacturer’s 
instructions (Roche). The experiment was repeated in 
three independent experiments. 
Statistical analysis
Student’s t test (for parametric data) and the 
Mann-Whitney test (for non-parametric data) were used. 
Statistical analyses on clinicopathological correlation were 
performed using the SPSS version 13.0 software (SPSS, 
Chicago, IL, USA). A p-value was considered significant 
when less than 0.05.
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RESULTS
Sox7 is frequently down-regulated and is 
associated with high Wnt/β-catenin signaling 
activity in endometrial cancer 
Emerging reports have documented that Sox7 
is down-regulated in several human cancers and may 
be a negative regulator of Wnt/β-catenin signaling 
activity [18-20]. As aberrant activation of Wnt/β-catenin 
signaling [8, 21], we thus firstly evaluated the expression 
status of Sox7 in endometrial carcinoma. By real-time 
quantitative RT-PCR (Q-PCR) analysis, we found that 
the expression levels of Sox7 in endometrial cancer was 
4.2-fold less than normal endometrium (P = 0.005) (see 
Supplementary Fig. 1). To investigate the association of 
Sox7 expression with Wnt/β-catenin signaling activity 
in endometrial carcinoma, two common Wnt/β-catenin 
specific targets in endometrioid type cancers; Fibroblast 
growth factor 9 (FGF9) and Stratifin (SFN) [22, 23] were 
selected for Q-PCR analysis. Our finding showed that 
there was a reciprocal relationship between Sox7 and 
the levels of FGF9 and SFN which were 17.9-fold (P = 
0.048) and 7.27-fold (P = 0.008), respectively, higher in 
endometrial cancer as compared with normal endometrium 
(see Supplementary Fig. 1). To further investigate the 
expression status of Sox7 and Wnt/β-catenin activity, we 
evaluated the expressions of Sox7, β-catenin, CyclinD1 
and FGF9 by immunohistochemical analysis on a human 
endometrial cancer array (EMC1501, Pantomics, Inc). 
Positive staining for Sox7 expression was detected in 
100% (5/5) of normal and atypical hyperplasia, while 
42.5% (51/120) of endometrioid endometrial cancer 
samples showed relatively lower or undetectable levels 
of Sox7(Table 1). Moreover, we observed that Sox7 
expressed mainly in nucleus and partially in cytoplasm 
of endometrial cancer cells (Fig. 1A). Clinicopathological 
correlation revealed that the down-regulated Sox7 was 
significantly associated with high-grade tumor (P = 
0.021) and high level of β-catenin (P = 0.038). On the 
other hand, we found that 51.7% (62/120) endometrial 
cancer cases showed relatively higher in β-catenin 
expression (>2.7 folds) (Table 2), but only  20% (1/5) 
of normal and atypical hyperplasia cases showed higher 
β-catenin in cytoplasm and at membrane. In contrast to 
Sox7, the upregulated β-catenin was correlated with high-
grade tumor (P = 0.045), and two Wnt/β-catenin specific 
downstream targets; Cyclin D1 (P < 0.001) and FGF9 (P 
= 0.003) [23, 24]. This indicates that there is a trend of 
inverse expression pattern between Sox7 and β-catenin in 
Table 1: Clinicopathological correlation of Sox7 expression in endometrial cancer 
tissue array (EMC1501) (Pantomics, CA, USA).
Characteristics Total
 Sox7 expression (fold change)
   < 2.2 folds  > 2.2 folds p
All cases   120 51 (42.5%)  69 (57.5%)
Stage
Early (1) 84  55 (65.5%)   29 (34.5%)
Late (2+3) 34 20 (58.8%)  14 (41.2%)  0.531
Grade
Low  (1+2) 66 38 (57.6%)  28 (42.4%)
High (3) 40 32 (80.0%)    8 (20.0%) 0.021*
Lymph Node Metastasis
Absence 95  60 (63.2%) 35 (36.8%)
Presence 23  15 (65.2%)  8 (34.8%) 1.000 
β-catenin
<2.7 folds 58 42 (72.4%) 16 (27.6%)
>2.7 folds 62  33 (53.2%)  29 (46.8%)  0.038*
CyclinD1
 <2.5 folds 56  45 (80.4%)  11 (19.6%)
>2.5 folds 64 30 (46.9%) 34 (53.1%) <0.001*
FGF9
<3.0 folds  51  43 (84.3%)    8 (15.7%)
>3.0 folds 69 32 (46.4%) 37 (53.6%)   <0.001*
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endometrial cancer. 
To investigate the suppression effects of Sox7 
on Wnt/β-catenin activity of endometrial cancer, we 
particularly examined the expression levels of CyclinD1 
and FGF9 in β-catenin highly expressing endometrial 
cancer samples which had either with or without 
expression of Sox7. IHC analysis displayed that both 
CyclinD1 and FGF9 were expressed as highly as β-catenin 
in Sox7 underexpressed sample (Fig. 1A). In contrast, 
both CyclinD1 and FGF9 were remarkably reduced in 
Sox7 expressing sample (Fig. 1A). We also evaluated 
the expression of Sox7 in human endometrial cancer 
cell lines by Q-PCR analysis. Of 5 endometrial cell lines 
(RL95, KLE, HEC-1B, HEC-1A, Ishikawa and an ovarian 
endometrioid carcinoma cell line (OEA) (TOV112D) 
), HEC-1A, HEC-1B, Ishikawa and TOV112D which 
have previously showed high Wnt/β-catenin signaling 
activity [22, 25] expressed lower Sox7 but higher levels 
of CyclinD1, C-myc and FGF9 (Fig. 1B) Taken together, 
these findings suggest that Sox7 may be a negative 
Figure 1: Sox7 is frequently underexpressed and inversely correlated with Wnt/β-catenin signaling in endometrial 
cancer. (A) Immunohistochemical analysis showed the presence of Sox7 could significantly reduce the expressions of CyclinD1 and FGF9 
in β-catenin overexpressing endometrial cancer (x20). Nuclear Sox7, CyclinD1 and FGF9 immunoreactivities were commonly found in 
endometrial cancer. The immunoreactivity of β-catenin could be found in the nucleus, cytoplasm and membrane. (B) Real time quantitative 
RT-PCR analysis showed that underexpressed Sox7 was correlated with the increased expressions of CyclinD1, FGF9 and C-myc in Wnt/β-
catenin signaling active endometrial cancer cell lines (HEC1B, HEC1A and Ishikawa) and an OEA cell line (TOV112D).
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regulator of Wnt/β-catenin signaling activity and is 
frequently down-regulated in endometrial cancer.  
Sox7 is a negative regulator of Wnt/β-catenin 
signaling
To further demonstrate that Sox7 is able to suppress 
Wnt/β-catenin activity, we performed TOPFlash reporter 
assay using HEK293 cells [16]. Transfection of Wnt-
1 expressing construct into HEK293 cells resulted in a 
7.8-fold increase in β-catenin transcriptional activity. 
When Sox7 was co-transfected with Wnt-1, the β-catenin 
transcriptional activity was inhibited in a dose-dependent 
manner of Sox7 (P < 0.01) (Fig. 2A). Moreover, stably 
ectopic expression of Sox7 could remarkably reduce two 
Wnt/β-catenin downstream targets; C-myc and CyclinD1, 
in two Sox-7 deficient cell lines; HEC-1A and TOV112D, 
in a dose-dependent manner (Fig. 2B). Intriguingly, this 
inhibitory effect of Sox7 on Wnt/β-catenin signaling was 
not only restricted in wild-type β-catenin endometrial 
cancer cell line (HEC-1A) but also in mutant β-catenin 
OEA cells (TOV-112D) (Fig. 2B). Taken together, these 
data further implicate that Sox7 has inhibitory effect 
on Wnt/β-catenin activity in endometrial cancer cells 
harboring not only wild-type but also mutant β-catenin.
Sox7 impedes Wnt/β-catenin signaling mediated 
endometrial cancer cell growth
As the aberrant activation of Wnt/β-catenin 
signaling is involved in promoting cancer cell growth, it 
is of interest to examine the suppressive role of Sox7 in 
the cell growth capacity of endometrial cancer. We firstly 
generated stable expressing Sox7 clones in a wild-type 
β-catenin cell line HEC-1A (C2 and C9), and a mutant 
β-catenin cell line TOV112D (C5 and C6). Western 
blotting showed that the ectopic expression of Sox7 was 
accompanied with the reduced expression of CyclinD1 
and C-myc in all clones of both cell lines (Fig. 3A & 
3B). When co-treatment of Wnt3A conditioned medium, 
HEC-1A with wild-type β-catenin was markedly elevated 
in β-catenin, CyclinD1 and C-myc expressions. But the 
enforced expression of Sox7 could inhibit both CyclinD1 
and C-myc significantly (Fig. 3A). On the other hand, the 
level of mutant β-catenin in TOV112D could not further 
be elevated upon treatment of Wnt3A, while Sox7 still had 
a suppressive effect on the expressions of CyclinD1 and 
C-myc (Fig. 3B). With XTT cell proliferation assay, we 
found that the Sox7 stably expressing clones of HEC-1A 
(C2 and C9) (P < 0.02) and TOV112D (C5 and C6) (P < 
0.01) exhibited significant reduction of cell proliferation 
rate (28 to 35%) as compared with their vector controls 
(Fig. 3C & 3D). Upon treatment of Wnt3A conditioned 
medium, all Sox7 stable expressing clones in HEC-1A 
(P < 0.001) and TOV112D (P < 0.001) further displayed 
Table 2: Clinicopathological correlation of β-catenin expression in endometrial 
cancer tissue array (EMC1501) (Pantomics, CA, USA).
Characteristics Total
 β-catenin expression (fold change)
  < 2.7 folds     > 2.7 folds p
All cases   120 58 (48.3%)  62 (51.7%)
Stage
Early (1) 84  44 (52.3%)   40 (47.7%)
Late (2+3) 34 14 (41.2%) 20 (58.8%) 0.313
Grade
Low  (1+2) 66 37 (56.1%)  29 (43.9%)
High (3) 40 14 (35.0%)  26 (65.0%) 0.045*
Lymph Node Metastasis
Absence 95 50 (52.6%) 45 (47.4%)
Presence 23  8 (34.8%) 15 (65.2%) 0.164
CyclinD1
 <2.5 folds 56 38 (67.9%) 18 (32.1%)
>2.5 folds 64 20 (31.3%)  44 (68.7%)  <0.001*
FGF9
<3.0 folds  51  33 (64.7%) 18 (35.3%)
>3.0 folds 69 25 (36.2%) 44 (63.8%)  0.003*
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suppressive effect on cell proliferation rate as compared 
with their vector controls (Fig. 3C & 3D). These data 
suggest that Sox7 exerts inhibitory effect on Wnt/β-catenin 
signalling mediated cell growth in endometrial cancer 
cells.
Sox7 interacts with wild-type and mutant 
β-catenin, as well as TCF4  
Given that Sox7 can negatively regulate Wnt/β-
catenin signaling activity through reduction of its 
downstream targets, it may interrupt the transcriptional 
activity of this pathway. Therefore, we were interested in 
whether Sox7 would interact with transcriptional factor 
complex β-catenin/TCF/LEF. We firstly examined the 
localization of Sox7, β-catenin and TCF4 in endometrial 
cancer cells, HEC-1A. By immunofluorescent microscopy, 
we demonstrated that RFP/Sox7 or GFP/Sox7 was 
localized mainly in the nucleus (Fig. 4A). Similarly, 
both GFP/mutant β-catenin S37A and Flag/TCF4 were 
also localized in the nucleus (Fig. 4A), indicating that 
all of these factors were co-localized in the nucleus 
of endometrial cancer cells. On the other hand, by co-
immunoprecipitation assay, the Flag/Sox7 could strongly 
interact with HA/β-catenin, GFP/mutant β-catenin S37A, 
as well as Myc/TCF4 (Fig. 4B). These data indicate that 
Sox7 could interact with multiple factors such as wild-
type and mutant β−catenin, as well as TCF4 in the nucleus 
of endometrial cancer cells. The interaction of Sox7 with 
these factors may impair the transcription activity of 
Figure 2: Sox7 is able to negatively regulate Wnt/β-catenin signaling activity. (A) Sox7 could reduce Wnt-1 induce 
TOPFLASH luciferase activity dose dependently in HEK293 cells. FOPFLASH luciferase activity was used as a negative control. (B) 
Transient transfection of Flag/Sox could remarkably reduce the expressions of C-myc and cyclinD1 in HEC1A (wild-type β-catenin) and 
TOV112D (mutant β-catenin) cells.
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β-catenin/TCF/LEF transcriptional factor complex.
DISCUSSION
This study showed that Sox7 was a potent negative 
regulator in the Wnt/β-catenin signaling pathway and 
was frequently underexpressed in endometrial cancer. 
The underexpressed Sox7 was associated with increased 
Wnt/β-catenin signaling activity and high-grade 
endometrial cancer. Importantly, we demonstrated that the 
enforced expression of Sox7 remarkably impeded Wnt/β-
catenin signaling mediated cancer cell growth and such 
suppressive effect was independent on the presence of 
wild-type or mutant β-catenin in endometrial cancer or 
OEA cells.  
Previous studies documented that approximately 
40% of endometrial cancer have aberrant activation 
of Wnt/β-catenin signaling pathway [7, 8]. Most of the 
cases are due to oncogenic mutations in the β-catenin, 
APC and Axins [7, 8].  Interestingly, many studies have 
demonstrated that the endometrioid-type of endometrial 
cancer and ovarian cancer have similar Wnt/β-catenin 
abnormalities [9, 10]. Our findings from IHC analysis 
showed that β-catenin was highly expressed in the nuclei, 
cytoplasm and membrane of endometrial cancer samples. 
Figure 3: Enforced expression of Sox7 inhibits not only Wnt/β-catenin signaling activity but also cell growth of 
endometrial cancer cells. (A) Western blotting showed Sox7 could suppress the expressions of C-myc and CyclinD1 in Sox7 stable 
expression clones in HEC1A and TOV112D cultured in normal and Wnt3A condition media. (B) XTT cell proliferation assay demonstrated 
that Sox7 could significantly inhibit cell growth of Sox7 stable expression clones in HEC1A and TOV112D cultured in normal and Wnt3A 
condition media.
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Clinic-pathological analysis revealed that the upregulated 
β-catenin was correlated with high-grade tumor. 
Intriguingly, Sox7 was commonly down-regulated in 
endometrial cancer samples. This finding is in agreement 
with previous reports on that the dysregulation of Wnt/β-
catenin signaling pathway is linked to the advanced-stage 
of human colorectal, lung and prostate cancers [19, 20, 
26]. On the other hand, the underexpressed Sox7, in 
contrast to β-catenin, was also associated with high-grade 
tumor. This indicates that the expressions of Sox7 and 
β-catenin have an inverse relationship. Our IHC result 
showed that Sox was localized mainly in the nuclei and 
partially in cytoplasm. We noted that some endometrial 
cancer cases with overexpressed β-catenin were also in 
concomitant with highly expressed Sox7. Interestingly, we 
observed that the highly expressed Sox7 was associated 
with the reduced expressions of CyclinD1 and FGF9 
in these overexpressed β-catenin endometrial cancer 
samples, suggesting Sox7 has a negative regulatory 
role in suppressing Wnt/β-catenin signaling activity in 
endometrial cancer. In fact, using endometrial cancer 
and OEA cells lines as cell models further supported our 
notion that Sox7 could negatively regulate Wnt/β-catenin 
signaling activity and its tumorigenic capacities.
Mounting evidences have showed that aberrant 
activation of the Wnt/β-catenin signaling has associated 
with human cancers including endometrial cancer and 
ovarian endometrioid adenocarcinoma (OEA) [27-29]. 
Figure 4: Sox7 interacts with β-catenin and TCF4 in the nucleus of endometrial cancer cells. (A) Immunofluorescent 
analysis showed that Sox7 (RFP-Sox7 (red) and GRF-Sox7(green)) co-localized with mutant β-catenin (GFP-mβ-Cat)(green) and Flag/
TCF4 (red) in the nucleus of HEC1A cells. (B) Co-immunoprecipitation assay showed that Sox7 (Flag/Sox7) could interact with wild-type 
β-catenin (HA/β-catenin), mutant β-catenin (GFP/β-catenin mutant), and TCF4 (Myc/TCF4). IgG was used as a control antibody. Ly, total 
lysate control.
Oncotarget 2012; 3: 1546-15561555www.impactjournals.com/oncotarget
Therefore, targeting Wnt/β-catenin signaling cascade 
is a potential good therapeutic approach to human 
cancers. The primary mediator of the oncogenic effects 
in this signaling pathway is β-catenin. Numerous studies 
have demonstrated that targeting the upstream effectors 
is able to inhibit Wnt/β-catenin signaling activity by 
reducing the level of β-catenin [30-33]. However, genetic 
mutation in β-catenin found in some human cancers such 
as endometrial cancer and OEA hinders the therapeutic 
approach of using inhibitors against upstream effectors 
in Wnt/β-catenin signaling cascade [34-36]. On the 
other hand, targeting the β-catenin/TCF protein complex 
will be a better choice in suppression of Wnt/β-catenin 
signaling activity. Indeed, numerous studies using small 
molecules have shown to inhibit this signaling activity 
successfully [37, 38]. Here we report Sox7 is a negative 
regulator of Wnt/β-catenin signaling and maybe a putative 
potential target in inhibition of this pathway activity. Our 
findings in this study provided several lines of evidence 
suggesting that Sox7 could suppress the transcriptional 
activity of β-catenin/TCF protein complex which 
harbors either wild-type or mutant β-catenin. According 
to our immunofluorescent microscopy, the nuclear 
co-localization indicated that there was a functional 
interaction among Sox7, β-catenin and TCF4. Indeed, 
further co-immunoprecipitation assay supported our 
notion of that there was a direct physical interaction 
between Sox7 with either β-catenin and TCF4. Based 
on these evidences, we hypothesized that the interaction 
of Sox7 might disrupt the transcriptional function of 
β-catenin/TCF/LEF-1 complex. However, further studies 
to investigate the interacting region and the binding effects 
of Sox7 and with β-catenin and TCF4 are warranted.
Although further studies are needed to delineate how 
the interaction of Sox7 mediated inhibition of -catenin/
TCF/LEF-1 complex transcriptional activity, our findings 
collectively highlight the suppressive roles of Sox7 in 
Wnt/β-catenin signaling and its tumorigenic capacities 
in endometrial cancer cells carrying either wild-type or 
mutant β-catenin. 
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